β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy

Diabetes, Obesity and Metabolism

Volumn 19, Issue , 2017, Pages 22-29

  Seino, Susumu ^a   Sugawara, Kenji ^a   Yokoi, Norihide ^a   Takahashi, Harumi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Epac2A; glutamate; in silico similarity search; incretin; KATP channel; sulfonylurea; cell

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; G PROTEIN COUPLED RECEPTOR 40; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOKINASE ACTIVATOR; INCRETIN; INSULIN; MITIGLINIDE; NATEGLINIDE; PROTEIN COUPLED RECEPTOR 40 AGONIST; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; NEW DRUG;

ANTIDIABETIC ACTIVITY; BINDING AFFINITY; COMBINATION DRUG THERAPY; DIABETES CONTROL; DIABETES MELLITUS; DRUG PROTEIN BINDING; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 85028997896     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12995     Document Type: Review

References (77)

1. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000;49:1751-1760.
2. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8:369-385.
3. Seino S, Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol Rev. 2005;85:1303-1342.
4. Inagaki N, Gonoi T, Clement JPt, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270:1166-1170.
5. Sakura H, Ammala C, Smith PA, Gribble FM, Ashcroft FM. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. FEBS Lett. 1995;377:338-344.
6. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998;47:1412-1418.
7. Aguilar-Bryan L, Clement JPt, Gonzalez G, Kunjilwar K, Babenko A, Bryan J. Toward understanding the assembly and structure of KATP channels. Physiol Rev. 1998;78:227-245.
8. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol. 1999;61:337-362.
9. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes. 2004;53(suppl 3):S156-S164.
10. Ashfield R, Gribble FM, Ashcroft SJ, Ashcroft FM. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel. Diabetes. 1999;48:1341-1347.
11. Mikhailov MV, Mikhailova EA, Ashcroft SJ. Molecular structure of the glibenclamide binding site of the beta-cell K(ATP) channel. FEBS Lett. 2001;499:154-160.
12. Vila-Carriles WH, Zhao G, Bryan J. Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J. 2007;21:18-25.
13. Li N, Wu JX, Ding D, Cheng J, Gao N, Chen L. Structure of a pancreatic ATP-sensitive potassium channel. Cell. 2017;168:101-110.e110.
14. Martin GM, Yoshioka C, Rex EA, et al. Cryo-EM structure of the ATP-sensitive potassium channel illuminates mechanisms of assembly and gating. Elife. 2017;6:e24149.
15. Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325:607-610.
16. Kashima Y, Miki T, Shibasaki T, et al. Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem. 2001;276:46046-46053.
17. Ozaki N, Shibasaki T, Kashima Y, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol. 2000;2:805-811.
18. Takahashi T, Shibasaki T, Takahashi H, et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013;6:ra94.
19. Shibasaki T, Takahashi T, Takahashi H, Seino S. Cooperation between cAMP signalling and sulfonylurea in insulin secretion. Diabetes Obes Metab. 2014;16(suppl 1):118-125.
20. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007;322:1-7.
21. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig. 2013;4:108-130.
22. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
23. Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199-207.
24. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci. 2006;31:680-686.
25. Sugawara K, Shibasaki T, Takahashi H, Seino S. Structure and functional roles of Epac2 (Rapgef4). Gene. 2016;575:577-583.
26. Niimura M, Miki T, Shibasaki T, Fujimoto W, Iwanaga T, Seino S. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. J Cell Physiol. 2009;219:652-658.
27. Ueno H, Shibasaki T, Iwanaga T, et al. Characterization of the gene EPAC2: structure, chromosomal localization, tissue expression, and identification of the liver-specific isoform. Genomics. 2001;78:91-98.
28. Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A. 2007;104:19333-19338.
29. Yasuda T, Shibasaki T, Minami K, et al. Rim2alpha determines docking and priming states in insulin granule exocytosis. Cell Metab. 2010;12:117-129.
30. Fujimoto K, Shibasaki T, Yokoi N, et al. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. J Biol Chem. 2002;277:50497-50502.
31. Shibasaki T, Sunaga Y, Fujimoto K, Kashima Y, Seino S. Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent Ca2+ channel in insulin granule exocytosis. J Biol Chem. 2004;279:7956-7961.
32. Kang G, Chepurny OG, Malester B, et al. cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells. J Physiol. 2006;573:595-609.
33. Kang G, Chepurny OG, Holz GG. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+ -induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol. 2001;536:375-385.
34. Schmidt M, Evellin S, Weernink PA, et al. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nat Cell Biol. 2001;3:1020-1024.
35. Dzhura I, Chepurny OG, Leech CA, et al. Phospholipase C-epsilon links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. Islets. 2011;3:121-128.
36. Dzhura I, Chepurny OG, Kelley GG, et al. Epac2-dependent mobilization of intracellular Ca(2)+ by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in beta-cells of phospholipase C-epsilon knockout mice. J Physiol. 2010;588:4871-4889.
37. Song C, Satoh T, Edamatsu H, et al. Differential roles of Ras and Rap1 in growth factor-dependent activation of phospholipase C epsilon. Oncogene. 2002;21:8105-8113.
38. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of cAMP sensor Epac. J Physiol. 2006;577:5-15.
39. Gromada J, Dissing S, Bokvist K, et al. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes. 1995;44:767-774.
40. Holz GG, Leech CA, Heller RS, Castonguay M, Habener JF. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem. 1999;274:14147-14156.
41. Kang G, Joseph JW, Chepurny OG, et al. Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells. J Biol Chem. 2003;278:8279-8285.
42. Park JH, Kim SJ, Park SH, et al. Glucagon-like peptide-1 enhances glucokinase activity in pancreatic beta-cells through the association of Epac2 with Rim2 and Rab3A. Endocrinology. 2012;153:574-582.
43. Gheni G, Ogura M, Iwasaki M, et al. Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. Cell Rep. 2014;9:661-673.
44. Eto K, Tsubamoto Y, Terauchi Y, et al. Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. Science. 1999;283:981-985.
45. MacDonald MJ. Evidence for the malate aspartate shuttle in pancreatic islets. Arch Biochem Biophys. 1982;213:643-649.
46. Omote H, Miyaji T, Juge N, Moriyama Y. Vesicular neurotransmitter transporter: bioenergetics and regulation of glutamate transport. Biochemistry. 2011;50:5558-5565.
47. Maechler P, Wollheim CB. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature. 1999;402:685-689.
48. Bertrand G, Ishiyama N, Nenquin M, Ravier MA, Henquin JC. The elevation of glutamate content and the amplification of insulin secretion in glucose-stimulated pancreatic islets are not causally related. J Biol Chem. 2002;277:32883-32891.
49. MacDonald MJ, Fahien LA. Glutamate is not a messenger in insulin secretion. J Biol Chem. 2000;275:34025-34027.
50. Marquard J, Otter S, Welters A, et al. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med. 2015;21:363-372.
51. Kubota A, Yabe D, Kanamori A, et al. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig. 2014;5:445-448.
52. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
53. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5:475-477.
54. Takahashi H, Shibasaki T, Park JH, et al. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes. 2015;64:1262-1272.
55. de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. 2007;56:438-443.
56. Crespin SR, Greenough WB 3rd, Steinberg D. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest. 1969;48:1934-1943.
57. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes. 1998;47:1613-1618.
58. Stein DT, Esser V, Stevenson BE, et al. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest. 1996;97:2728-2735.
59. Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278:11303-11311.
60. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422:173-176.
61. Latour MG, Alquier T, Oseid E, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes. 2007;56:1087-1094.
62. Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006;148:619-628.
63. Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes. 2009;58:1067-1076.
64. Mancini AD, Poitout V. GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit. Diabetes Obes Metab. 2015;17:622-629.
65. Ferdaoussi M, Bergeron V, Zarrouki B, et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia. 2012;55:2682-2692.
66. Moran BM, Flatt PR, McKillop AM. G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis. Acta Diabetol. 2016;53:177-188.
67. Srivastava A, Yano J, Hirozane Y, et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature. 2014;513:124-127.
68. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301:370-373.
69. Efanov AM, Barrett DG, Brenner MB, et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology. 2005;146:3696-3701.
70. Futamura M, Hosaka H, Kadotani A, et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem. 2006;281:37668-37674.
71. Fyfe MC, White JR, Taylor A, et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia. 2007;50:1277-1287.
72. Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes. 2007;56:1694-1702.
73. Nakamura A, Terauchi Y, Ohyama S, et al. Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass. Endocrinology. 2009;150:1147-1154.
74. Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2560-2566.
75. Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2013;15:750-759.
76. Drwal MN, Griffith R. Combination of ligand- and structure-based methods in virtual screening. Drug Discov Today Technol. 2013;10:e395-e401.
77. Sugawara K, Honda K, Reien Y, et al. A novel diphenylthiosemicarbazide is a potential insulin secretagogue for anti-diabetic agent. PLoS One. 2016;11:e0164785.